The FDA has approved the SetPoint System, a neuroimmune modulation device, for the treatment of adults with moderately to severely active rheumatoid arthritis.

The agency’s decision was based on the outcomes of the double-blind, randomised, sham-controlled RESET-RA study.

SetPoint Medical, a company dedicated to developing therapies for people living with chronic autoimmune diseases, today ...

The device stimulates the vagus nerve, signaling the body to tamp down the inflammation that contributes to the disease.

The SetPoint System is an implanted device that stimulates the vagus nerve once a day. It was tested through a clinical trial at Northwell Health.

SetPoint Medical announced today that the FDA approved its SetPoint neuroimmune modulation system for treating rheumatoid ...

SetPoint System offers the first clinically-proven neuromodulation treatment option for rheumatoid arthritis (RA) SetPoint Medical, a company dedicated to developing therapies for people living ...

SetPoint Medical's vagus nerve stimulator has received FDA approval for treating moderate-to-severe rheumatoid arthritis (RA) ...

SetPoint Medical, a company dedicated to developing therapies for people living with chronic autoimmune diseases, today announced that the U.S. Food and Drug ...

US FDA approves SetPoint Medical’s novel neuroimmune modulation device, SetPoint System for rheumatoid arthritis: Valencia, California Saturday, August 2, 2025, 17:00 Hrs [IST] ...